Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

被引：3

作者：

Iskierka-Jazdzewska, Elzbieta ^{[1
]}

Kim, Won Seog ^{[2
]}

Cho, Seok-Goo ^{[3
]}

Kim, Tae Min ^{[4
]}

Jarque, Isidro ^{[5
]}

Robak, Tadeusz ^{[6
]}

Poon, Michelle ^{[7
]}

Prince, H. Miles ^{[8
,9
]}

Yong, Sung ^{[10
]}

Lim, Francesca ^{[11
]}

Carpio, Cecilia ^{[12
]}

Tan, Tran-Der ^{[13
]}

Ayyappan, Sabarish ^{[14
]}

Gutierrez, Antonio ^{[15
]}

Zhang, Huilai ^{[16
]}

Cao, Junning ^{[17
,18
]}

Zhang, Mingzhi ^{[19
,20
]}

Tessoulin, Benoit ^{[21
,22
]}

Li, Jingjin ^{[23
]}

Ivanescu, Cristina ^{[24
]}

机构：

[1] Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland

[2] Samsung Med Ctr, Ctr Hematol Malignancy, Seoul, South Korea

[3] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[5] Hosp Univ La Fe, Valencia, Spain

[6] Med Univ Lodz, Lodz, Poland

[7] Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore

[8] Epworth Healthcare, Melbourne, Vic, Australia

[9] Univ Melbourne, Melbourne, Vic, Australia

[10] Dong A Univ Hosp, Busan, South Korea

[11] Singapore Gen Hosp, Singapore, Singapore

[12] Vall DHebron Hosp, Barcelona, Spain

[13] Koo Fdn Sun Yat Sen Canc Ctr, Taipei, Taiwan

[14] Univ Iowa Hosp & Clin, Iowa City, IA USA

[15] Hosp Univ Son Espases, IdISBa Palma, Palma de Mallorca, Spain

[16] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China

[17] Fudan Univ, Dept Lymphoma, Shanghai Canc Ctr, Shanghai, Peoples R China

[18] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[19] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[20] Lymphoma Diag & Treatment Ctr Henan Prov, Zhengzhou, Peoples R China

[21] Nantes Univ, Sch Med, Nantes, France

[22] Univ Hosp Nantes, Nantes, France

[23] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[24] IQVIA, Amsterdam, Netherlands

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180743

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[41] A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma
Wagner-Johnston, Nina D.
Goy, Andre
Rodriguez, Maria A.
Ehmann, W. Christopher
Hamlin, Paul A.
Radford, John
Thieblemont, Catherine
Suh, Cheolwon
Sweetenham, John
Huang, Yifan
Sullivan, Sharon T.
Vandendries, Erik R.
Gisselbrecht, Christian
LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2863 - 2869
[42] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO
Martin Garcia-Sancho, A.
Baile, M.
Rodriguez, G.
Dlouhy, I.
Sancho, J. M.
Jarque, I.
Gonzalez-Barca, E.
Salar, A.
Espeso, M.
Grande, C.
Bergua, J.
Montes-Moreno, S.
Redondo, A.
Enjuanes, A.
Campo, E.
Lopez-Guillermo, A.
Caballero, D.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (02) : 202 - 211
[43] Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma
Yang, Haiyan
Xiang, Bing
Song, Yuqin
Zhang, Huilai
Zhao, Weili
Zou, Dehui
Lv, Fangfang
Guo, Wei
Liu, Aichun
Li, Caixia
Tan, Ziwen
Liu, Yang
Fu, Lina
Guo, Haiyi
Novotny, William
Huang, Jane
Li, Yufu
BLOOD ADVANCES, 2022, 6 (06) : 1629 - 1636
[44] Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ohmachi, Ken
Niitsu, Nozomi
Uchida, Toshiki
Kim, Seok Jin
Ando, Kiyoshi
Takahashi, Naoki
Takahashi, Naoto
Uike, Naokuni
Eom, Hyeon Seok
Chae, Yee Soo
Terauchi, Takashi
Tateishi, Ukihide
Tatsumi, Mitsuaki
Kim, Won Seog
Tobinai, Kensei
Suh, Cheolwon
Ogura, Michinori
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2103 - +
[45] A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
Larsen, Thomas S.
Manzke, Oliver
Leibovitz, Daniel
Arbushites, Michael
BLOOD, 2022, 140 : 12077 - 12078
[46] A MULTICENTER PHASE II STUDY OF BENDAMUSTINE WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Kim, W. S.
Ando, K.
Niitsu, N.
Ogura, M.
Takahashi, N.
Uike, N.
Eom, H. Seok
Chae, Y. S.
Tobinai, K.
Terauchi, T.
Tateishi, U.
Tatsumi, M.
Suh, C.
ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
[47] A prognostic nomogram constructed for relapsed or refractory diffuse large B-cell lymphoma patients
Jiang, Shiyu
Qin, Yan
Liu, Peng
Yang, Jianliang
Yang, Sheng
He, Xiaohui
Zhou, Shengyu
Gui, Lin
Zhang, Changgong
Zhou, Liqiang
Sun, Yan
Shi, Yuankai
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (02) : E11 - E16
[48] DeVIC chemotherapy is effective for patients with refractory or relapsed diffuse large B-cell lymphoma
Okada, Kazuya
Sakai, Kazuya
Muranushi, Hiroyuki
Okamoto, Yusuke
Sugiura, Hiroyuki
Sato, Aki
Sato, Takayuki
Maeda, Takeshi
Onishi, Tatsuhito
Ueda, Yasunori
ANNALS OF ONCOLOGY, 2015, 26 : 108 - 108
[49] Phase 2 Search Study:XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Song, Yuqin
Cai, Qingqing
Zhang, Qingyuan
Sun, Xiuhua
Yang, Haiyan
Yao, Zhihua
Zou, Liqun
Zhang, Liling
Cao, Junning
Wang, Tingyu
Li, Lanfang
Liu, Yao
Jing, Hongmei
Gao, Sujun
Ding, Kaiyang
Liu, Bingshan
Zhao, Jun
Zhu, Jun
BLOOD, 2023, 142
[50] Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase II Study
Bennani, N. Nora
Atherton, Pamela
Steinert, Kimberly O.
Rimsza, Lisa M.
Tun, Aung M.
Hoffmann, Marc S.
Narkhede, Mayur S.
Vaidya, Rakhee
Said, Rabih
Shapiro, Geoffrey I.
Costello, Brian A.
Ansell, Stephen M.
Nowakowski, Grzegorz S.
BLOOD, 2023, 142

← 1 2 3 4 5 →